In 2015 the founders of Symbiotic Health demonstrated the utility of an oral formulation of fecal derived bacteria to treat recurrent C.difficile infection.
Following that success, Symbiotic Health developed a 2nd generation capsule formulation which is currently being used for pre-clinical studies of our lead therapeutic candidate, SHP-01.
The 2nd generation formulation is compatible with both protein and cellular cargo, enabling Symbiotic to actively negotiate with academic and private entities to secure our next lead.
SHP-01 is the lead therapeutic in the Symbiotic Health pipeline for the treatment of acute and recurrent C.difficile infection. It is a novel narrow spectrum antimicrobial enzyme (lysin) which targets diverse clinical strains of C.difficile while sparing healthy gut bacteria required for health. This molecule was invented in the laboratory of Vincent Fischetti at The Rockefeller University. Symbiotic Health has an exclusive license for commercial development of this molecule for human therapeutic applications.
Unlike newly developed antibody and phage therapeutics, SHP-01 is a stable oral formulation, facilitating administration.
SHP-01 can be co-administered with antibiotics, the current standard of care, unlike bacteria-based therapies.
As concerns about antibiotic resistance are paramount in modern healthcare, SHP-01 belongs to a class of molecules that have no known resistance mechanism in the environment.
SHP-01 offers several advantages over both traditional and newly developed therapies for C.difficile.
SHP-01 is intended for the treatment of acute and recurrent infection.
Antibiotics are currently used for the treatment of acute infection. Unlike antibiotics, SHP-01 is microbiome sparing.